Metagenomi, Inc. (NASDAQ:MGX) Receives $10.00 Consensus Target Price from Analysts

Shares of Metagenomi, Inc. (NASDAQ:MGX) have been given a consensus rating of “Moderate Buy” by the five brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $10.00.

Several equities research analysts have commented on the stock. Wall Street Zen cut shares of Metagenomi from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Metagenomi in a research report on Monday, December 22nd.

Metagenomi Stock Down 4.4%

NASDAQ MGX opened at $1.41 on Friday. The firm’s 50 day moving average is $1.56 and its 200-day moving average is $1.91. The company has a market capitalization of $52.86 million, a PE ratio of -0.59 and a beta of 0.45. Metagenomi has a 12-month low of $1.23 and a 12-month high of $3.95.

Metagenomi (NASDAQ:MGX) last announced its earnings results on Thursday, March 5th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.02). Metagenomi had a negative return on equity of 47.14% and a negative net margin of 348.54%.The business had revenue of $3.91 million for the quarter, compared to analyst estimates of $7.33 million. As a group, sell-side analysts expect that Metagenomi will post -2.46 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE raised its stake in shares of Metagenomi by 482.9% during the 4th quarter. Bank of America Corp DE now owns 21,113 shares of the company’s stock worth $76,000 after purchasing an additional 17,491 shares in the last quarter. AQR Capital Management LLC bought a new position in shares of Metagenomi in the first quarter valued at $119,000. Norges Bank bought a new position in shares of Metagenomi in the second quarter valued at $373,000. Pura Vida Investments LLC increased its holdings in Metagenomi by 260.1% during the second quarter. Pura Vida Investments LLC now owns 952,134 shares of the company’s stock worth $1,409,000 after buying an additional 687,743 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in Metagenomi during the second quarter worth $222,000.

About Metagenomi

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.